Tatsuhiko Azegami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tatsuhiko Azegami has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
Kaori Hayashi
Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
36 shared publicationsHiroshi Itoh
Center for Preventive Medicine Keio University Hospital Tokyo Japan
25 shared publicationsTakashin Nakayama
Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
17 shared publicationsAkihito Hishikawa
Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
16 shared publicationsAkinori Hashiguchi
Department of Pathology, Keio University School of Medicine, Tokyo, Japan
15 shared publicationsNorifumi Yoshimoto
Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
15 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Wiley in Nephrology
- Vol. 31 (9) , e70285
Salt Intake and Kidney Outcomes in Older Adults With Chronic Kidney Disease: A Stage‐Specific Cohort Study
Aim: In patients with chronic kidney disease (CKD), salt restriction has been shown to lower blood pressure and proteinuria and to provide kidney protective effects. However, the benefit of salt restriction in older adults with CKD remains unclear, particularly in advanced stages. Methods: We conducted a single‐center retrospective cohort study of patients aged ≥ 75 years with CKD (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m 2 ). Salt intake was estimated from spot urine using the Tanaka formula and categorized into quartiles. The primary outcome was a composite kidney endpoint of ≥ 30% eGFR decline or initiation of kidney replacement therapy. Cox proportional hazards models and competing risk analyses were performed, stratified by CKD stage. Results: A total of 462 patients (median age, 79 years; 68.6% male) were included. Of these, 305 had CKD Stage 3 and 157 had Stages 4–5. During a median follow‐up of 2.79 years, 121 patients (26.2%) experienced the composite outcome. In Stage 3 CKD, higher salt intake was significantly associated with increased risk (adjusted HR 2.70; 95% CI 1.02–7.12; highest vs. lowest quartile), and findings were consistent across sensitivity analyses. In contrast, no significant association was observed in Stages 4–5. Conclusion: Among older adults with CKD, excessive salt intake was associated with adverse kidney outcomes in CKD Stage 3 but not in Stages 4–5. These results suggest that salt restriction may be most beneficial in the early stages of CKD in this population.
- 17 September 2026
- Published by Wiley in Nephrology
- Vol. 31 (9) , e70285
Open AccessSalt Intake and Kidney Outcomes in Older Adults With Chronic Kidney Disease: A Stage‐Specific Cohort Study
Aim: In patients with chronic kidney disease (CKD), salt restriction has been shown to lower blood pressure and proteinuria and to provide kidney protective effects. However, the benefit of salt restriction in older adults with CKD remains unclear, particularly in advanced stages. Methods: We conducted a single‐center retrospective cohort study of patients aged ≥ 75 years with CKD (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m 2 ). Salt intake was estimated from spot urine using the Tanaka formula and categorized into quartiles. The primary outcome was a composite kidney endpoint of ≥ 30% eGFR decline or initiation of kidney replacement therapy. Cox proportional hazards models and competing risk analyses were performed, stratified by CKD stage. Results: A total of 462 patients (median age, 79 years; 68.6% male) were included. Of these, 305 had CKD Stage 3 and 157 had Stages 4–5. During a median follow‐up of 2.79 years, 121 patients (26.2%) experienced the composite outcome. In Stage 3 CKD, higher salt intake was significantly associated with increased risk (adjusted HR 2.70; 95% CI 1.02–7.12; highest vs. lowest quartile), and findings were consistent across sensitivity analyses. In contrast, no significant association was observed in Stages 4–5. Conclusion: Among older adults with CKD, excessive salt intake was associated with adverse kidney outcomes in CKD Stage 3 but not in Stages 4–5. These results suggest that salt restriction may be most beneficial in the early stages of CKD in this population.
- 2 September 2026
- Published by Springer Nature in CEN Case Reports
- Vol. 15 (5) , 139
Biopsy-proven kidney-limited thrombotic microangiopathy associated with bevacizumab and pegylated liposomal doxorubicin: a case with a biphasic clinical course
- 2 September 2026
- Published by Springer Nature in CEN Case Reports
- Vol. 15 (5) , 139
Biopsy-proven kidney-limited thrombotic microangiopathy associated with bevacizumab and pegylated liposomal doxorubicin: a case with a biphasic clinical course
- Open Access
- 26 August 2026
- Published by Elsevier in Kidney International Case Reports
- Vol. 1 (4)
An Unusual Pattern of Basement Membrane–Predominant Kidney Calcium Deposition in a Liver Transplant Recipient: A Case Report
- 26 August 2026
- Published by Elsevier in Kidney International Case Reports
- Vol. 1 (4)
Open AccessAn Unusual Pattern of Basement Membrane–Predominant Kidney Calcium Deposition in a Liver Transplant Recipient: A Case Report
- Open Access
- 10 August 2026
- Published by Elsevier in General Hospital Psychiatry
- Vol. 102, 179-186
Mental disorders and subsequent kidney function decline: A nationwide cohort study in Japan
- 10 August 2026
- Published by Elsevier in General Hospital Psychiatry
- Vol. 102, 179-186
Open AccessMental disorders and subsequent kidney function decline: A nationwide cohort study in Japan
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Mental Disorders and Subsequent Kidney Function Decline: A Nationwide Cohort Study in Japan
Background: Mental disorders are associated with multiple medical conditions, but a comprehensive assessment of their association with kidney function decline is limited. We examined this association in a large population-based cohort. Methods: We conducted a retrospective cohort study using nationwide claims data linked to health checkup records (January 2006–July 2024). Baseline mental disorders were defined using ICD-10 codes and categorized into 10 groups. The primary outcome was a composite kidney outcome: incident end-stage kidney disease, initiation of kidney replacement therapy, or a ≥30% decline in estimated glomerular filtration rate. Results: Among 2,989,648 individuals (median age, 45 years [IQR, 37–53]; 60.5% men), 301,715 (10.1%) had at least one mental disorder. Over a median follow-up of 1,252 days (IQR, 728–1,805), 31,996 individuals experienced the composite kidney outcome. In multivariable Cox models, seven of the 10 categories were significantly associated with the outcome; the highest hazard ratios (HRs) were observed for personality disorders (HR 2.37 [95% CI, 1.55–3.64]), organic disorders (HR 1.80 [95% CI, 1.41–2.31]), and eating disorders (HR 1.69 [95% CI, 1.32–2.16]). Overall, the presence of any mental disorder was associated with a higher risk of the composite outcome (HR 1.12 [95% CI, 1.09–1.16]), with a dose–response relationship by the number of mental disorder categories (HR 2.51 [95% CI, 1.86–3.39] for ≥4 categories). Conclusions: Most categories of mental disorders were associated with subsequent kidney function decline in this nationwide cohort, suggesting that kidney surveillance may be warranted for adults with mental disorders.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMental Disorders and Subsequent Kidney Function Decline: A Nationwide Cohort Study in Japan
Background: Mental disorders are associated with multiple medical conditions, but a comprehensive assessment of their association with kidney function decline is limited. We examined this association in a large population-based cohort. Methods: We conducted a retrospective cohort study using nationwide claims data linked to health checkup records (January 2006–July 2024). Baseline mental disorders were defined using ICD-10 codes and categorized into 10 groups. The primary outcome was a composite kidney outcome: incident end-stage kidney disease, initiation of kidney replacement therapy, or a ≥30% decline in estimated glomerular filtration rate. Results: Among 2,989,648 individuals (median age, 45 years [IQR, 37–53]; 60.5% men), 301,715 (10.1%) had at least one mental disorder. Over a median follow-up of 1,252 days (IQR, 728–1,805), 31,996 individuals experienced the composite kidney outcome. In multivariable Cox models, seven of the 10 categories were significantly associated with the outcome; the highest hazard ratios (HRs) were observed for personality disorders (HR 2.37 [95% CI, 1.55–3.64]), organic disorders (HR 1.80 [95% CI, 1.41–2.31]), and eating disorders (HR 1.69 [95% CI, 1.32–2.16]). Overall, the presence of any mental disorder was associated with a higher risk of the composite outcome (HR 1.12 [95% CI, 1.09–1.16]), with a dose–response relationship by the number of mental disorder categories (HR 2.51 [95% CI, 1.86–3.39] for ≥4 categories). Conclusions: Most categories of mental disorders were associated with subsequent kidney function decline in this nationwide cohort, suggesting that kidney surveillance may be warranted for adults with mental disorders.
- Open Access
- 24 July 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 88 (4) , 631-635
Long-Term Clinical Course of COL4A1-Associated Nephropathy and Assessment of α1 Chain of Type IV Collagen Expression in Kidney Biopsy Specimens: A Case Report
- 24 July 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 88 (4) , 631-635
Open AccessLong-Term Clinical Course of COL4A1-Associated Nephropathy and Assessment of α1 Chain of Type IV Collagen Expression in Kidney Biopsy Specimens: A Case Report
- Open Access
- 26 May 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (9) , 1998-2007
Clinical Relevance of Calcium Measures
Key Points: Ionized calcium showed the strongest associations with the QT interval, whereas total and corrected calcium showed weaker associations. Calcium measures that correlated better with ionized calcium did not necessarily perform better for QT-based outcomes. These findings reinforced ionized calcium as the most clinically valid reference and supported outcome-based calcium assessment. Background: Ionized calcium (iCa) is the physiologically active fraction of circulating calcium, whereas total calcium (tCa) and albumin-corrected calcium (cCa) remain widely used. Despite growing concerns over the accuracy of correction formulas, most evaluations rely on concordance with iCa rather than meaningful physiologic outcomes. We compared iCa, tCa, and cCa and assessed their clinical validity using ventricular repolarization—reflected by the QT interval—as a physiologic end point. Methods: This single-center cross-sectional observational study included adults who visited our outpatient department with simultaneous measurements of iCa, tCa, electrolytes, albumin, and electrocardiography. iCa, tCa, and seven albumin-correction formulas were examined. Associations with the QT interval were evaluated using linear regression and restricted cubic splines; logistic regression assessed corrected QT prolongation. Sensitivity analyses included alternative QT-correction methods and analyses in hypoalbuminemia. Results: Among 647 participants (median age 68 years; 54% male), common comorbidities included hypertension (33%), diabetes (18%), and cardiac disease (11%). Correlations between iCa and other calcium measures varied widely. In fully adjusted analyses, iCa demonstrated the strongest association with QT interval (standardized β =−0.22; 95% confidence interval, −0.29 to −0.14). tCa and all cCa exhibited substantially weaker associations. Although some tCa and cCa demonstrated relatively higher correlation with iCa, they exhibited weaker associations with QT. In hypoalbuminemia (albumin n =118), agreement with iCa declined for all cCa, and associations with QT were attenuated; only iCa (standardized β =−0.25; 95% confidence interval, −0.44 to −0.06) and limited formulas (notably Payne) retained modest associations. Conclusions: iCa is the physiologically and clinically valid measure of calcium status consistently demonstrating the strongest associations with ventricular repolarization. By contrast, tCa and cCa demonstrate substantially reduced clinical relevance and numerical concordance with iCa does not reflect clinical validity. These findings support outcome-based validation of calcium measure and reinforce the importance of direct iCa measurement.
- 26 May 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (9) , 1998-2007
Open AccessClinical Relevance of Calcium Measures
Key Points: Ionized calcium showed the strongest associations with the QT interval, whereas total and corrected calcium showed weaker associations. Calcium measures that correlated better with ionized calcium did not necessarily perform better for QT-based outcomes. These findings reinforced ionized calcium as the most clinically valid reference and supported outcome-based calcium assessment. Background: Ionized calcium (iCa) is the physiologically active fraction of circulating calcium, whereas total calcium (tCa) and albumin-corrected calcium (cCa) remain widely used. Despite growing concerns over the accuracy of correction formulas, most evaluations rely on concordance with iCa rather than meaningful physiologic outcomes. We compared iCa, tCa, and cCa and assessed their clinical validity using ventricular repolarization—reflected by the QT interval—as a physiologic end point. Methods: This single-center cross-sectional observational study included adults who visited our outpatient department with simultaneous measurements of iCa, tCa, electrolytes, albumin, and electrocardiography. iCa, tCa, and seven albumin-correction formulas were examined. Associations with the QT interval were evaluated using linear regression and restricted cubic splines; logistic regression assessed corrected QT prolongation. Sensitivity analyses included alternative QT-correction methods and analyses in hypoalbuminemia. Results: Among 647 participants (median age 68 years; 54% male), common comorbidities included hypertension (33%), diabetes (18%), and cardiac disease (11%). Correlations between iCa and other calcium measures varied widely. In fully adjusted analyses, iCa demonstrated the strongest association with QT interval (standardized β =−0.22; 95% confidence interval, −0.29 to −0.14). tCa and all cCa exhibited substantially weaker associations. Although some tCa and cCa demonstrated relatively higher correlation with iCa, they exhibited weaker associations with QT. In hypoalbuminemia (albumin n =118), agreement with iCa declined for all cCa, and associations with QT were attenuated; only iCa (standardized β =−0.25; 95% confidence interval, −0.44 to −0.06) and limited formulas (notably Payne) retained modest associations. Conclusions: iCa is the physiologically and clinically valid measure of calcium status consistently demonstrating the strongest associations with ventricular repolarization. By contrast, tCa and cCa demonstrate substantially reduced clinical relevance and numerical concordance with iCa does not reflect clinical validity. These findings support outcome-based validation of calcium measure and reinforce the importance of direct iCa measurement.
- 11 May 2026
- Published by Springer Nature in CEN Case Reports
- Vol. 15 (3) , 86
Kidney-limited thrombotic microangiopathy caused by relative hypertension in a hemodynamically vulnerable kidney allograft, mimicking malignant hypertension
Malignant hypertension is traditionally defined as severe systemic blood pressure elevation accompanied by end-organ damage. In kidney transplant recipients, however, kidney allografts may be particularly vulnerable to hypertensive injury even at lower blood pressure levels, owing to impaired autoregulation associated with denervation and calcineurin inhibitor exposure. We report a 52-year-old kidney transplant recipient presenting with severe kidney injury (serum creatinine, 4.90 mg/dL) 16 months after transplantation. Although systemic blood pressure remained within the range of 140–170/90–105 mmHg—below the classical threshold of malignant hypertension—an allograft biopsy revealed the lesions suggestive of thrombotic microangiopathy (TMA), including mesangiolysis and edematous intimal thickening of the arteries. After exclusion of antibody-mediated rejection, calcineurin inhibitor toxicity, and primary TMAs, the patient was diagnosed with kidney-limited TMA attributable to relative hypertension producing a malignant hypertension-like phenotype in the setting of graft-specific vulnerability. Given the presumed contribution of the renin-angiotensin system (RAS)-mediated vascular injury, an angiotensin II receptor blocker was initiated despite severe kidney dysfunction, resulting in marked improvement in kidney function and proteinuria. This case illustrates that kidney allografts may develop a malignant hypertension-like pathophysiology with kidney-limited TMA at blood pressure levels below the classical malignant range. Awareness of this discrepancy may help clinicians recognize atypical hypertensive injury in transplant recipients, and early RAS blockade may be considered as a potential strategy to preserve allograft function, even in the setting of severe kidney injury.
- 11 May 2026
- Published by Springer Nature in CEN Case Reports
- Vol. 15 (3) , 86
Kidney-limited thrombotic microangiopathy caused by relative hypertension in a hemodynamically vulnerable kidney allograft, mimicking malignant hypertension
Malignant hypertension is traditionally defined as severe systemic blood pressure elevation accompanied by end-organ damage. In kidney transplant recipients, however, kidney allografts may be particularly vulnerable to hypertensive injury even at lower blood pressure levels, owing to impaired autoregulation associated with denervation and calcineurin inhibitor exposure. We report a 52-year-old kidney transplant recipient presenting with severe kidney injury (serum creatinine, 4.90 mg/dL) 16 months after transplantation. Although systemic blood pressure remained within the range of 140–170/90–105 mmHg—below the classical threshold of malignant hypertension—an allograft biopsy revealed the lesions suggestive of thrombotic microangiopathy (TMA), including mesangiolysis and edematous intimal thickening of the arteries. After exclusion of antibody-mediated rejection, calcineurin inhibitor toxicity, and primary TMAs, the patient was diagnosed with kidney-limited TMA attributable to relative hypertension producing a malignant hypertension-like phenotype in the setting of graft-specific vulnerability. Given the presumed contribution of the renin-angiotensin system (RAS)-mediated vascular injury, an angiotensin II receptor blocker was initiated despite severe kidney dysfunction, resulting in marked improvement in kidney function and proteinuria. This case illustrates that kidney allografts may develop a malignant hypertension-like pathophysiology with kidney-limited TMA at blood pressure levels below the classical malignant range. Awareness of this discrepancy may help clinicians recognize atypical hypertensive injury in transplant recipients, and early RAS blockade may be considered as a potential strategy to preserve allograft function, even in the setting of severe kidney injury.
- Open Access
- 21 April 2026
- Published by Wiley in Aging Cell
- Vol. 25 (5) , e70509
The Mitochondrial NAD Transporter SLC25A51 in Adipocytes Regulates Adipose Tissue Mitochondrial Function and Systemic Metabolism During Aging
Nicotinamide adenine dinucleotide (NAD) is a classical coenzyme regulating cellular energy metabolism. Emerging evidence demonstrates the causal relationship between defective NAD metabolism and various age‐associated diseases. The major purpose of the present study was to investigate the role of adipocyte mitochondrial NAD biology in age‐associated metabolic diseases. To this end, we focused on solute carrier family 25 member 51 (SLC25A51), a recently identified mitochondrial NAD transporter. We found that aging was associated with decreased adipose tissue SLC25A51 expression in both humans and mice. We next generated and analyzed novel knockout and overexpression models, which we have named adipocyte‐specific Slc25a51 knockout (ASKO) and Slc25a51 overexpressing (ASLO) mice. ASKO mice had a marked decrease in adipose tissue mitochondrial NAD levels and exhibited age‐associated systemic metabolic complications, such as obesity, glucose intolerance, insulin resistance, hyperinsulinemia, metabolic inflexibility, dyslipidemia, and hepatosteatosis. Mechanistically, loss of Slc25a51 reduced mitochondrial respiratory function, fatty acid oxidation capacity, and adiponectin production in adipose tissue, likely contributing to the development of systemic metabolic complications. Conversely, ASLO mice were protected from obesity and insulin resistance caused by aging. In conclusion, our results provide novel mechanistic and therapeutic insights into understanding the critical role of adipocyte mitochondrial NAD transporter SLC25A51 in the pathophysiology of age‐associated metabolic diseases, particularly obesity and insulin resistance.
- 21 April 2026
- Published by Wiley in Aging Cell
- Vol. 25 (5) , e70509
Open AccessThe Mitochondrial NAD Transporter SLC25A51 in Adipocytes Regulates Adipose Tissue Mitochondrial Function and Systemic Metabolism During Aging
Nicotinamide adenine dinucleotide (NAD) is a classical coenzyme regulating cellular energy metabolism. Emerging evidence demonstrates the causal relationship between defective NAD metabolism and various age‐associated diseases. The major purpose of the present study was to investigate the role of adipocyte mitochondrial NAD biology in age‐associated metabolic diseases. To this end, we focused on solute carrier family 25 member 51 (SLC25A51), a recently identified mitochondrial NAD transporter. We found that aging was associated with decreased adipose tissue SLC25A51 expression in both humans and mice. We next generated and analyzed novel knockout and overexpression models, which we have named adipocyte‐specific Slc25a51 knockout (ASKO) and Slc25a51 overexpressing (ASLO) mice. ASKO mice had a marked decrease in adipose tissue mitochondrial NAD levels and exhibited age‐associated systemic metabolic complications, such as obesity, glucose intolerance, insulin resistance, hyperinsulinemia, metabolic inflexibility, dyslipidemia, and hepatosteatosis. Mechanistically, loss of Slc25a51 reduced mitochondrial respiratory function, fatty acid oxidation capacity, and adiponectin production in adipose tissue, likely contributing to the development of systemic metabolic complications. Conversely, ASLO mice were protected from obesity and insulin resistance caused by aging. In conclusion, our results provide novel mechanistic and therapeutic insights into understanding the critical role of adipocyte mitochondrial NAD transporter SLC25A51 in the pathophysiology of age‐associated metabolic diseases, particularly obesity and insulin resistance.
- Open Access
- 15 April 2026
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
Parkinson disease imposes risk of kidney function decline
Background and hypothesis: Parkinson disease is associated with systemic complications, but its impact on kidney function in the general population remains unclear. This study examined whether Parkinson disease is associated with an increased risk of kidney function decline in a large population-based cohort. Methods: This retrospective cohort study used nationwide claims data that were linked to health checkup records (April 2014–August 2024). Individuals were classified according to the presence or absence of Parkinson disease at baseline using International Classification of Diseases, 10th Revision codes. The primary outcome was a composite kidney outcome, defined as incident end-stage kidney disease, initiation of kidney replacement therapy, or a ≥30% decline in estimated glomerular filtration rate. Results: In the overall cohort of 1 659 421 individuals, the median age was 68 years (IQR, 61–72) and 41.9% were men; 11 497 (0.7%) had Parkinson disease. Over a median follow-up of 1092 days (IQR, 631–1 520), 33 335 individuals reached the composite kidney outcome. Kaplan–Meier estimates showed a higher risk of the composite kidney outcome in individuals with Parkinson disease than in those without Parkinson disease (log-rank P < 0.001).In multivariable Cox models, Parkinson disease was independently associated with the composite kidney outcome [hazard ratio 1.91 (95% confidence interval 1.72–2.12)]. Conclusions: In this nationwide cohort, Parkinson disease was independently associated with subsequent kidney function decline. These findings support closer monitoring of kidney function in adults with Parkinson disease.
- 15 April 2026
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
Open AccessParkinson disease imposes risk of kidney function decline
Background and hypothesis: Parkinson disease is associated with systemic complications, but its impact on kidney function in the general population remains unclear. This study examined whether Parkinson disease is associated with an increased risk of kidney function decline in a large population-based cohort. Methods: This retrospective cohort study used nationwide claims data that were linked to health checkup records (April 2014–August 2024). Individuals were classified according to the presence or absence of Parkinson disease at baseline using International Classification of Diseases, 10th Revision codes. The primary outcome was a composite kidney outcome, defined as incident end-stage kidney disease, initiation of kidney replacement therapy, or a ≥30% decline in estimated glomerular filtration rate. Results: In the overall cohort of 1 659 421 individuals, the median age was 68 years (IQR, 61–72) and 41.9% were men; 11 497 (0.7%) had Parkinson disease. Over a median follow-up of 1092 days (IQR, 631–1 520), 33 335 individuals reached the composite kidney outcome. Kaplan–Meier estimates showed a higher risk of the composite kidney outcome in individuals with Parkinson disease than in those without Parkinson disease (log-rank P < 0.001).In multivariable Cox models, Parkinson disease was independently associated with the composite kidney outcome [hazard ratio 1.91 (95% confidence interval 1.72–2.12)]. Conclusions: In this nationwide cohort, Parkinson disease was independently associated with subsequent kidney function decline. These findings support closer monitoring of kidney function in adults with Parkinson disease.